OBJECTIVE: Men with type 2 diabetes have lower concomitant prostate-specific antigen (PSA) levels; however, the influence of metabolic conditions on PSA changes over time remains unknown. Therefore, the goal of this study was to assess associations between type 2 diabetes and hypertension and changes in serum PSA levels. METHODS: In 1990, a randomly selected cohort of Caucasian men, ages 40-79, from Olmsted County, MN completed questionnaires ascertaining demographic characteristics, current medical conditions and medications biennially, with 633 men undergoing blood draws. Men with a physician diagnosis of diabetes or hypertension at baseline, or who reported using medications to treat these conditions prior to baseline were considered exposed. Men with at least two serum PSA measurements (n = 569) were included in this analysis. Linear mixed models were used to estimate the annual percent change in serum PSA levels associated with diabetes and hypertension, adjusting for baseline age. RESULTS: The overall mean change in serum PSA levels was 3.6% per year and increased with age (P = .009). Men with diabetes experienced less annual change in serum PSA levels (1.1%) than did non-diabetic men (3.7%), adjusting for age (P = .02). Age-adjusted change in serum PSA levels differed little by hypertension status (3.7% vs. 3.6%; P = .49). CONCLUSIONS: Our results suggest that Caucasian men with type 2 diabetes experience smaller increases in serum PSA levels as they age compared to men without diabetes. Additional research is needed to elucidate whether this difference results in a relatively lower incidence of prostate cancer or less cancer detection among diabetic men. Copyright Â
OBJECTIVE:Men with type 2 diabetes have lower concomitant prostate-specific antigen (PSA) levels; however, the influence of metabolic conditions on PSA changes over time remains unknown. Therefore, the goal of this study was to assess associations between type 2 diabetes and hypertension and changes in serum PSA levels. METHODS: In 1990, a randomly selected cohort of Caucasian men, ages 40-79, from Olmsted County, MN completed questionnaires ascertaining demographic characteristics, current medical conditions and medications biennially, with 633 men undergoing blood draws. Men with a physician diagnosis of diabetes or hypertension at baseline, or who reported using medications to treat these conditions prior to baseline were considered exposed. Men with at least two serum PSA measurements (n = 569) were included in this analysis. Linear mixed models were used to estimate the annual percent change in serum PSA levels associated with diabetes and hypertension, adjusting for baseline age. RESULTS: The overall mean change in serum PSA levels was 3.6% per year and increased with age (P = .009). Men with diabetes experienced less annual change in serum PSA levels (1.1%) than did non-diabeticmen (3.7%), adjusting for age (P = .02). Age-adjusted change in serum PSA levels differed little by hypertension status (3.7% vs. 3.6%; P = .49). CONCLUSIONS: Our results suggest that Caucasian men with type 2 diabetes experience smaller increases in serum PSA levels as they age compared to men without diabetes. Additional research is needed to elucidate whether this difference results in a relatively lower incidence of prostate cancer or less cancer detection among diabeticmen. Copyright Â
Authors: Carmen Rodriguez; Alpa V Patel; Alison M Mondul; Eric J Jacobs; Michael J Thun; Eugenia E Calle Journal: Am J Epidemiol Date: 2005-01-15 Impact factor: 4.897
Authors: Jennifer L Beebe-Dimmer; Rodney L Dunn; Aruna V Sarma; James E Montie; Kathleen A Cooney Journal: Cancer Date: 2007-03-01 Impact factor: 6.860
Authors: Naomi M Gades; Debra J Jacobson; Michaela E McGree; Michael M Lieber; Rosebud O Roberts; Cynthia J Girman; Steven J Jacobsen Journal: BMC Med Res Methodol Date: 2006-12-14 Impact factor: 4.615
Authors: James N Mubiru; Magdalena Garcia-Forey; Nicole Cavazos; Peggah Hemmat; Edward J Dick; Michael A Owston; Cassondra A Bauer; Robert E Shade; Jeffrey Rogers Journal: Prostate Date: 2011-06-28 Impact factor: 4.104
Authors: Aruna V Sarma; James Hotaling; Rodney L Dunn; Patricia A Cleary; Barbara H Braffett; Catherine Kim; Catherine Martin; William Herman; Patricia Gatcomb; Alan M Jacobson; Sarah K Holt; Hunter Wessells Journal: J Urol Date: 2014-09-11 Impact factor: 7.450
Authors: Anna Barbosa-Desongles; Cristina Hernández; Ines De Torres; Francina Munell; Marie-France Poupon; Rafael Simó; David M Selva Journal: PLoS One Date: 2013-09-10 Impact factor: 3.240
Authors: Rachel Dankner; Paolo Boffetta; Lital Keinan-Boker; Ran D Balicer; Alla Berlin; Liraz Olmer; Havi Murad; Barbara Silverman; Moshe Hoshen; Laurence S Freedman Journal: Diabetologia Date: 2016-05-17 Impact factor: 10.122
Authors: Danielle Crawley; Florence Chamberlain; Hans Garmo; Sarah Rudman; Björn Zethelius; Lars Holmberg; Jan Adolfsson; Par Stattin; Paul Carroll; Mieke Van Hemelrijck Journal: Ecancermedicalscience Date: 2018-01-25